Home›Trial›NCT05092269
🔬NCT05092269Phase 3ACTIVE NOT RECRUITING

A Long-term Extension Study of Ustekinumab in Pediatric Participants

Study Summary

The purpose of this study is to collect long-term safety data of subcutaneous (SC) ustekinumab

Conditions
Crohn DiseaseColitis, UlcerativeArthritis, Psoriatic
Interventions / Drugs
Ustekinumab
View on ClinicalTrials.gov ↗
Sponsor
JNJ
Johnson & Johnson
Diversified Pharma
C60/100
Study Details
Enrollment159 participants
Primary Completion—
Lead SponsorJanssen Research & Development, LLC
Data Retrieved2026-04-11 02:55:31.550552+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.